Eli Lilly has surpassed $20 billion in acquisitions in 2026, a company record, as AI tools reshape the economics of drug development.1
The deals include Kelonia Therapeutics at $7 billion, Centessa Pharmaceuticals at $7.8 billion, and three vaccine developers totaling $3.8 billion.1
The strategic logic centers on AI. Drug discovery platforms powered by machine learning are compressing pre-clinical timelines, raising the value of early-stage pipeline assets.1 Companies that once needed a decade to validate a molecule can now move faster — and so can acquirers evaluating them.
For Lilly, the urgency is structural. The Prozac patent expiration in the 2000s triggered a prolonged revenue decline that took years to reverse.1 That experience shaped how the company now thinks about pipeline risk. Facing another potential cliff, Lilly is deploying capital externally rather than waiting for internal R&D to deliver.
The acquisition-over-R&D shift is not unique to Lilly, but the scale is. At more than $20 billion in a single year, Lilly is treating external deal flow as its primary pipeline engine — not a supplement to internal discovery.
AI reduces the friction in this model. Lower evaluation costs and faster integration of acquired science mean pharma companies can take earlier-stage bets without absorbing the full risk of pre-clinical failure.1 The pipeline assets Lilly is buying are earlier and more numerous than in past acquisition cycles.
Whether the strategy pays depends on execution. The test will be Lilly's R&D spend as a share of revenue over the next two years: if internal R&D falls while acquisition activity holds, the company will have structurally outsourced its discovery engine to AI-native biotechs.1
Peers with lower acquisition activity will provide a natural comparison. If Lilly's pipeline growth outpaces theirs, it will validate the bet that AI-era acquisitions can outperform traditional R&D investment — at least for companies willing to move at this speed and cost.